Regulon

Regulon is a privately held, oncology-focused, biopharmaceutical company with a proprietary, patent-protected and differentiated tumour-targeting nanotechnology that is being used to develop improved versions of leading chemotherapy drugs. Regulon's unique liposome encapsulation technology applicable to drugs, small molecules, peptides, proteins an... d viruses, significantly reduces the side effects of chemotherapy known to exacerbate the quality of life (QOL) of cancer patients. The firm has successfully applied this technology to encapsulate two members of the platinum family of anticancer drugs: cisplatin and oxaliplatin. Platins are the cornerstone of modern chemotherapy, as they have been commonly applied in the effective treatment of the majority of tumor indications for the last 30 years. Cisplatin was approved in 1978 and increased dramatically the prognosis of epithelial malignancies; as a result of its introduction into the arsenals of chemotherapy the cure rate of testicular cancer rose from 10% to 90%. And in spite of over 30 years of 'triumphal' discoveries in cancer drugs oncologists are turning back to cisplatin. Cisplatin operates by forming a platinum complex inside of a tumor cell which binds to DNA and cross-links DNA. When DNA is cross-linked in this manner, it causes the cells to undergo apoptosis (cell suicide due to DNA damage beyond repair). Liposomes are microscopic vesicles developed in a laboratory environment. Each liposome has an outer wall comprised of lipids, (non-water-soluble molecular organic compounds) similar and sometimes identical to those which compose an animal cell wall. This identical property allows liposomes to interact directly with cells.Read More